Eye injection showdown: which drug restores vision better in diabetes patients?
NCT ID NCT07338097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two common eye injection drugs, aflibercept and bevacizumab, in adults aged 30-60 with diabetic macular edema (fluid buildup in the retina causing vision loss). About 116 participants will receive monthly injections for two months. The goal is to see which drug improves vision more and reduces retinal swelling. This is not a cure but aims to ease symptoms and improve sight.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMH Institute of Medical Sciences
Multan, Punjab Province, 66000, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
- New syringe could simplify High-Dose eye treatment
- Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy